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Abstract
In their recent editorial, Baltussen and colleagues provide a concise summary of the prevailing discourse 
on priority-setting in health policy. Their perspective is entirely consistent with current practice, yet they 
unintentionally demonstrate the narrowness and moral precariousness of that discourse and practice. I respond 
with demonstrations of the importance of ‘interrogating scarcity’ in a variety of contexts. 
Keywords: Resource Allocation, Scarcity, Priority-Setting, Neoliberalism, Distributive Justice
Copyright: © 2017 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/
licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited.
Citation: Schrecker T. Priority setting: right answer to a far too narrow question? Comment on “Global 
developments in priority setting in health.” Int J Health Policy Manag. 2017;6(x):x–x. doi:10.15171/ijhpm.2017.66
*Correspondence to:
Ted Schrecker
Email: 
theodore.schrecker@durham.ac.uk
Article History:
Received: 16 April 2017
Accepted: 23 May 2017
ePublished: 30 May 2017
Commentary
School of Medicine, Pharmacy and Health, Durham University, University Boulevard, Stockton-on-Tees, UK.
http://ijhpm.com
Int J Health Policy Manag 2017, 6(x), 1–3 doi 10.15171/ijhpm.2017.66
In their recent editorial, Baltussen and colleagues1 provide a concise summary of the prevailing discourse on priority-setting in health policy. Their perspective is entirely 
consistent with current practice, yet they unintentionally 
demonstrate the narrowness and moral precariousness of 
that discourse and practice. In the high-income country 
context, they question neither the stratospheric pricing of 
new drugs nor the inevitability of fiscal austerity. In the 
context of lower-income countries, they address neither 
the unequal distributions of political resources that work 
against mobilising resources for health services domestically, 
nor the historical contribution to resource shortages of 
the large, rich countries that at least until very recently 
occupied the commanding heights of the world economy – 
and continue to exercise influence far outside their borders 
through multilateral institutions like the World Bank and the 
International Monetary Fund.
Each of these omissions merits brief elaboration. The 
drug prices they correctly cite as cause for concern2,3 are 
consequences of a dysfunctional regime for financing health 
innovation that rewards an industry with a long history 
of corporate criminality4,5 by providing expansive patent 
protection and unquestioning deference to the rights of owners 
of ‘intellectual property’ – a regime that is of relatively recent 
origin,6 albeit now imposed on much of the world through a 
process in which “in effect, twelve corporations made public 
law for the world”7 in the form of the TRIPS agreement. Fiscal 
austerity is, as has once again been pointed out in the United 
Kingdom, a political choice8 – one made in the larger context 
of a project of shrinking state expenditure to pre-World 
War II levels,9,10 even as the United Kingdom remains near 
the low end of the high-income country spectrum in terms 
of the share of its gross domestic product (GDP) devoted to 
public spending on healthcare. Crucially, at the macro-level 
of public finance, other jurisdictions are making different 
choices (Figure 1). 
Outside the high-income world, recent Chatham House 
work11 suggests that many countries could provide at least 
basic healthcare for all their residents through more effective 
mobilisation of domestic resources – a point Reeves and 
colleagues12 have made with specific reference to India, an 
under-performer on comparative health indicators that at 
the national level has embarked on a course of cutting public 
spending on health.13 It is the resistance of the privileged to 
even modest domestic redistribution that often stands in the 
way and creates the context for priority-setting. International 
influences are also implicated. The 2014 Ebola outbreak 
temporarily redirected attention to the debilitating effects on 
national health systems of decades of ‘structural adjustment’ 
nostrums promoted by the International Monetary Fund 
and the World Bank,14-16 recently using different labels, in 
an effort to protect creditor interests and diffuse neoliberal 
macroeconomic policies that have been widely discredited. 
Although some of the magnitudes remain contested,17 the 
high-income world is further implicated in facilitating 
capital flight and tax avoidance mechanisms that reduce the 
resources available to provide basic healthcare and related 
needs in many jurisdictions.18-20 And the intractable problem 
of massively inadequate research on diseases of the poor, who 
do not constitute an attractive market for the pharmaceutical 
industry,21,22 implies the need for urgent attention to priority-
setting in quite a different domain.
The usual axiom in priority-setting using cost-effectiveness 
analysis is that no matter how high the health budget is, it 
will never be sufficient to fulfil all demands and therefore 
priority setting will always be needed to ensure resources 
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are not wasted on interventions that do not buy much 
health. The axiom rests on a missing middle premise: that 
the current budget is the appropriate one. This premise 
must be interrogated. The presumption that the fiscal 
constraint imposed by the overall healthcare budget should 
be taken as given, and subjected neither to ethical nor 
political analysis, is questionable even under conditions of 
formal democracy, which are far from universal. That said, 
improving mechanisms for priority-setting is important, as is 
defending the integrity of highly regarded processes like those 
of the National Institute for Clinical and Health Excellence 
(NICE) in England23 – not least because these serve as a 
defence against the overblown claims of the pharmaceutical 
industry. However, better priority-setting that takes macro-
level resource constraints as given should not be the primary 
concern of health systems researchers. In setting priorities for 
their own work they could do more good, or at least less harm, 
by ‘interrogating scarcity’24: directing their attention and that 
of their audiences to the political choices, made domestically 
and internationally, that mean resources are scarce in some 
settings, and for some purposes, but not in and for others. 
In the UK context, various forms of covert and not-so-covert 
rationing25,26 will probably become routine, if that has not 
already happened. A 2015 Nuffield Trust briefing warned 
flatly that “the sum of all NICE commissioning guidance for 
an area would almost certainly be unaffordable”26; mainstream 
academic discussion of the future of the NHS now accepts “the 
inevitability of hard choices in healthcare.”27 Such acceptances 
come with little scrutiny of the disabling28 if not homicidal29 
impact of those choices, critique of the political commitments 
driving them, or acknowledgement that they seldom affect 
the rich. (The Bank of England now advertises that its Deputy 
Governors’ compensation package includes private medical 
insurance; see Figure 2).
At the Birmingham conference referred to in the editorial, 
many participants were preoccupied with how to defend ‘de-
commissioning’ of NHS services – obfuscatory jargon for 
making them available only to those with deep pockets. The 
Figure 1. General Government Spending as % of GDP, Selected Countries, Actual and Anticipated.
Source: Data from International Monetary Fund World Economic Outlook database, April 2017. This is an updated version of a figure published for 
earlier years in various venues by Peter Taylor-Gooby.
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Figure 2. Public Health Cover in the United Kingdom: Not Good Enough for Some.
Schrecker
International Journal of Health Policy and Management, 2017, 6(x), 1–3 3
conference also featured a session on “Understanding how 
neoliberalism threatens health, and how to fight back” (full 
disclosure: organised by the author). One can only wish the 
editorial’s authors had attended.
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